BMO Capital Believes Cooper Co (NYSE: COO) Won’t Stop Here

In a report released today, Joanne Wuensch from BMO Capital maintained a Buy rating on Cooper Co (COOResearch Report), with a price target of $306. The company’s shares closed yesterday at $277.03, close to its 52-week high of $283.18.

According to, Wuensch is a 5-star analyst with an average return of 12.1% and a 70.8% success rate. Wuensch covers the Healthcare sector, focusing on stocks such as Boston Scientific Corp, Zimmer Biomet Holdings, and Baxter International.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Cooper Co with a $296.40 average price target, which is a 7.0% upside from current levels. In a report released today, Piper Jaffray also maintained a Buy rating on the stock with a $300 price target.


See today’s analyst top recommended stocks >>

The company has a one-year high of $283.18 and a one-year low of $216.47. Currently, Cooper Co has an average volume of 299.3K.

Based on the recent corporate insider activity of 49 insiders, corporate insider sentiment is negative on the stock. Most recently, in September 2018, Thomas A. Bender, a Director at COO sold 7,150 shares for a total of $1,925,855.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

The Cooper Cos, Inc. operates as a medical device company. It operates through the following business units: Cooper Vision and Cooper Surgical. The Cooper Vision business unit brings a refreshing perspective on vision care with a commitment to crafting quality lenses for contact lens wearers.

Leave a Reply

Your email address will not be published. Required fields are marked *